SCHEMBL6086480

SCHEMBL6086480

Cc1ccc2nc(-c3c[nH]nc3-c3ccc(NC(=O)C4(C(N)=O)CC4)cc3)oc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
POLB P06746 1/20 0.48
CETP P11597 2/20 0.47
AGPAT2 O15120 1/20 0.45
BAZ1A Q9NRL2 1/20 0.44
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
ATM Q13315 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
RXFP1 Q9HBX9 1/20 0.42
TP53 P04637 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086086 0.89 MAPT (0.50) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6085628 0.85 KDM4E (0.51) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6084464 0.85 MAPT (0.47) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6087573 0.85 MAPT (0.51) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6086552 0.83 CEPT1 (0.49) MAPTSMN1; SMN2CETPAGPAT2NPC1
SCHEMBL6085303 0.81 MAPT (0.50) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6085906 0.80 MAPT (0.53) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6086313 0.80 CETP (0.56) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6085746 0.79 AGPAT2 (0.53) MAPTSMN1; SMN2POLBCETPAGPAT2
SCHEMBL6085049 0.78 CETP (0.50) MAPTSMN1; SMN2POLBCETPAGPAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP disclosed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885SMN1; SMN2 831/4885POLB 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.